Drug Approval | September 23, 2024
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Stable profits, low leverage to keep credit profiles comfortable
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Subscribe To Our Newsletter & Stay Updated
